Desmopressin Acetate

  • # LGM Pharma is a Desmopressin Acetate CAS# 62288-83-9 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, samples, sourcing, purity and more.
  • # Questions? Call our customer API support number 1-(800)-881-8210.
  • # LGM Pharma offers this active ingredient but not the finished dosage forms.
  • Inquire about this product >>

Product Details:

  • Product Name: Desmopressin Acetate
  • CAS #: 62288-83-9
  • Mode of Action:

    Desmopressin emulates the actions of endogenous human ADH (refer to Pharmacology section above). Desmpressin is a structural analogue of ADH modified by deamination of 1-cysteine and substitution of 8-L-arginine by 8-D-arginine. Compared to natural ADH, desmopressin elicits a great antidiuretic response on weight basis.

  • Pharmacodynamics:

    Desmopressin is a synthetic analogue of the natural antidiuretic hormone (ADH or vasopressin) that is produced by the hypothalamus and stored in the posterior pituitary gland. The main function of ADH is to regulate extracellular fluid volume in the body. ADH secretion is stimulated by angiotensin II, linking it to the renin-angiotensin-aldosterone system (RAAS). ADH stimulates water reabsorption in the kidneys by causing the insertion of aquaporin-2 channels on the apical surface of cells of the DCT and collecting tubules. It also causes vasoconstriction through its action on vascular smooth muscle cells of the collecting tubules. The efficacy of desmopressin for managing bleeds in patients with hemophilia A or von Willebrand’s disease Type I arises from its ability to elicit dose-dependent increases in plasma factor VIII (antihemophilic factor), plasminogen activator, and to a lesser extent, factor VIII-related antigen and ristocetin cofactor activities; these changes improve blood clotting.

  • Metabolism:

    Metabolic fate unknown. Is not affected by liver microsomal cytochrome P450 enzymes.

  • Toxicity:

    Overdose may lead to increased duration of action and lead to symptoms such as fluid retention, headaches, abdominal cramps, nausea, and facial flushing. Adverse effects include headache, nausea, abdominal pain, facial flushing, dizziness, dry mouth, and hyponatremia. Nasal congestion and rhinitis have been reported with nasal spray formulations.

  • IUPAC: Vasopressin, 1-(3-mercaptopropanoic acid)-8-D-arginine-, monoacetate (salt)
  • ATC: H01BA02
  • PubChem: 5311065
  • DrugBank: DB00035 (BIOD00061, BIOD00112, BTD00061, BTD00112)
  • Formula: C46-H64-N14-O12-S2.C2-H4-O2
  • Molecular Mass: 1129.28
  • Synonyms: 1-(3-Mercaptopropionic acid)-8-D-arginine vasopression monoacetate, Concentraid, DDAVP, DDAVP (needs no refrigeration), DDAVP Nasal Spray, DDAVP Rhinal Tube, Demopressin acetate, Desmopressin acetate, Desmopressin acetate (needs NO refrigeration), Desmopressin acetate preservative free, Minirin, Minirine, Octostim, Stimate, Stimate Nasal Spray, UNII-1K12647SFC
  • SMILES: N1(CCC[C@@H]1C(=O)N[C@@H](C(NCC(N)=O)=O)CCCNC(N)=N)C([C@@H]1CSSCCC(N[C@@H](C(N[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(N)=O)C(N1)=O)Cc1ccccc1)=O)Cc1ccc(cc1)O)=O)=O.CC(O)=O
  • AHFS Code: 08:28.0
  • General Reference:


    1. Leissinger C, Becton D, Cornell C Jr, Cox Gill J: High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A. Haemophilia. 2001 May;7(3):258-66. Pubmed
    2. Sequence Information Link


Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants


  • Technical packages as well as access to filed DMF,
    ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any
    submission type based on specific customer requirements

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service